Development and implementation of fluid biomarkers in neurodegenerative diseases
This group focuses on the development and implementation of biomarkers that are associated with neurodegenerative disorders and reflects other conditions of the brain. Examined mediums include CSF, blood, skin biopsies, and cells.
Biomarkers of interest to our group are linked to:
- Alzheimer’s disease and other neurodegenerative disorders
- General neurodegeneration
- Acute and chronic brain injury including both traumatic brain injury and stroke
- The neurovascular system
Platforms used include SIMOA, Mass spect, Mesoscale discovery, FACS, and ELISAs, but also novel technology development (nanotech) for isolating biomarkers.
In alignment with MultiPark's strategic goals
- To develop accurate and cost-effective diagnostics using minimally invasive methods (for selecting appropriate therapies in time (personalized medicine).
- To promote clinical implementation of cutting edge findings.
- Linking biomarker analysis to pathophysiology in neurodegeneration in order to understand disease mechanism and for detection, monitoring and prognosis of neurodegenerative disorders.
- Establish novel technologies for isolating biomarkers in relevant biofluids linked to neurodegenerative diseases.
- Accelerate scientific discoveries in the field of biomarkers by detection of synergies, increased collaborations and translation/implementation of new methods into the clinic.
Once a year, the group plans to organize workshops or symposia on techniques and/or the use of biomarkers.
sebastian [dot] palmqvist [at] med [dot] lu [dot] se (sebastian[dot]palmqvist[at]med[dot]lu[dot]se)